Together with our previously published data, we propose that such alterations change the fate of CD8+ T cell trafficking and CD8+ T cell-mediated immunity in EAC and may lead to their retention in the fractalkine-rich omentum where they contribute to pathological inflammation to the detriment of effective anti-tumor immunity. The gene discussed is CD8A; the disease is neoplasm.